[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-364060-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-364060-en":131},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","combination-of-lonidamine-with-devimistat-induces-synergistic-antitumor-effects-in-lung-cancer-via-multifaceted-disruption-of-cellular-energy-metabolism","Combination of lonidamine with devimistat induces synergistic antitumor effects in lung cancer via multifaceted disruption of cellular energy metabolism","","Combination of lonidamine with devimistat is evaluated as a cancer therapy strategy by targeting cellular energy metabolic pathways in non-small cell lung cancer. The study combines two inhibitors with complementary limitations to synergistically interfere with glycolysis, the tricarboxylic acid cycle, and oxidative phosphorylation. Synergy is assessed using in vitro and in vivo experiments including cytotoxicity, combination dosing, colony formation, mitochondrial function, ATP and ROS production, apoptosis, and pharmacodynamics. Metabolite profiling supports that metabolic disruption suppresses tumor growth while promoting ROS accumulation, ATP reduction, mitochondrial impairment, and apoptosis activation.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/combination-of-lonidamine-with-devimistat-induces-synergistic-antitumor-effects-in-lung-cancer-via-multifaceted-disruption-of-cellular-energy-metabolism/364060/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/combination-of-lonidamine-with-devimistat-induces-synergistic-antitumor-effects-in-lung-cancer-via-multifaceted-disruption-of-cellular-energy-metabolism/364060.png","ImageObject",300,407,{"name":42,"@type":43},"LangkahRina","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-13","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",11,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What therapeutic strategy does the study focus on for non-small cell lung cancer?","Question",{"text":63,"@type":64},"The study targets tumor cellular energy metabolism by combining lonidamine and devimistat to disrupt multiple metabolic pathways, including glycolysis, the TCA cycle, and oxidative phosphorylation.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How is the synergistic antitumor effect evaluated?",{"text":68,"@type":64},"The work tests synergy in vitro and in vivo using measures such as cytotoxicity, optimal combination doses, colony formation, mitochondrial function, ATP and ROS production, apoptosis, and pharmacodynamics in an axenograft mouse model.",{"name":70,"@type":61,"acceptedAnswer":71},"What biological effects does the combination produce in tumor cells?",{"text":72,"@type":64},"The combination increases ROS, reduces ATP generation, impairs mitochondrial morphology and function, and ultimately activates apoptosis through metabolic regulation.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},364060,1790390805,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,120,123,127],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":124,"doc_module":4,"doc_module_name":25,"category_name":125,"show_sort_weight":124,"slug":126},10,"Lifestyle","lifestyle",{"id":128,"doc_module":4,"doc_module_name":25,"category_name":129,"show_sort_weight":97,"slug":130},19,"General","general",{"code":4,"msg":82,"data":132},{"doc_id":79,"user_id":133,"nickname":42,"user_avatar":134,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":140,"language":141,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":12,"update_tm":145,"read_time":109,"preview_page_count":33,"preview_urls":146},962090893776,"https://ap-avatar.wpscdn.com/davatar_155a257f0dc6eb9ab79c44ca47cae57d","ONCOLOGY REPORTS 56: 178, 2026  \nCombination of lonidamine with devimistat induces synergistic antitumor effects in lung cancer via multifaceted disruption of cellular energy metabolism  \nXINHE BAI 1,2* , YONGFENG YANG 1,2* , YULING LUO 1 , PEI JING 1,2 , XIA HONG 1,2 , YAQIN ZOU 1,2 , YAN DAI 1,2 , XUPING YANG 1,2 , MEILING ZHOU 1,2 , HAN XIAO 1,2 , YILAN HUANG 1,2 , SHIWEI GUO 1,2 and QINGZE FAN 1,2  \n1Department of Pharmacy, Affiliated Hospital, Southwest Medical University, Luzhou, Sichuan 646000, P.R. China; 2  \nDepartment of Clinical Pharmacy, School of Pharmacy, Southwest Medical University, Luzhou, Sichuan 646000, P.R. China  \nReceived February 12, 2026; Accepted August 6, 2026  \nDOI: 10. 3892/or.2026.9184  \nAbstract. Disrupting energy metabolic pathways has emerged as a promising strategy for cancer therapy including non‑small cell lung cancer (NSCLC) . However, the ultimate anticancer effects have not been satisfactory. This is likely because cellular energy metabolism encompasses multiple processes and pathways, and tumor cells can flexibly regulate these processes and pathways to adapt to external disturbancesand changes in the microenvironment in order to maintain their growth and proliferation. As a result, current strategies which only target certain aspects of energy metabolism have not achieved commendable results. In the present study, two inhibitors lonidamine and devimistat, each with their own limitations, were combined to treat A549 NSCLC by syner‑ gistically interfering with the main aspects of cellular energy metabolism including glycolysis, the tricarboxylic acid cycle and oxidative phosphorylation. The synergistic potency was examined in vitro and in vivo including cytotoxicity, optimal combination doses, colony formation, mitochondrial function, adenosine triphosphate (ATP) and reactive oxygen species (ROS) production, apoptosis and pharmacodynamics in axenograft mouse model. Moreover, characteristic metabolite levels were measured to elucidate the effects of combination treatment on cellular energy metabolism. The results showed that this combination therapy could synergistically inhibit  \nCorrespondence to: Dr Qingze Fan or Professor Shiwei Guo, Department of Pharmacy, Affiliated Hospital, Southwest Medical University, 25 Taiping Street, Jiangyang, Luzhou, Sichuan 646000, P.R. China  \nE‑mail: [qingzefan017@swmu.edu.cn](qingzefan017@swmu.edu.cn)  \nE‑mail: [guoshiwei081@swmu.edu.cn](guoshiwei081@swmu.edu.cn)  \n*Contributed equally  \nKey words: non‑small cell lung cancer, devimistat, lonidamine, glycolysis, tricarboxylic acid cycle, oxidative phosphorylation, combination therapy  \ntumor growth in vitro and in vivo. Furthermore, combining these two metabolic inhibitors could induce the production of ROS, reduce the generation of ATP, impair mitochondrial morphology and function, and ultimately activate apoptosis in tumor cells through metabolic regulation, facilitating anti‑ tumor treatment. The findings underscore the necessity and effectiveness of targeting tumor energy metabolism for lung cancer therapy, providing reliable evidence that metabolic therapies can effectively participate in cancer treatment.  \nIntroduction  \nCancer is a notable public health issue worldwide, among which lung cancer (LC) represents the most commonly diagnosed cancer and the leading cause of death (1) . Traditionally, LC is classified into two main types: i) Non‑small cell LC (NSCLC); and ii) small cell LC, with the former accounting for ~85% of cases (2) . Traditional treatment modalities for NSCLC, including surgical treatment, chemotherapy and radiotherapy, have yet to fulfill the clinical demands. This underscores the necessity for ongoing research to develop novel therapeutic approaches (3) . Tumors, including those present in LC, are characterized by the rapid growth and proliferation of cancer cells, which requires a notable amount of adenosine triphos‑ phate (ATP) as an energy source and a substantial supply of me","cbCainH0JjVZqsMx","https://ap.wps.com/l/cbCainH0JjVZqsMx","pdf",14547345,16,"English","# Abstract\n# Introduction","[{\"question\":\"What therapeutic strategy does the study focus on for non-small cell lung cancer?\",\"answer\":\"The study targets tumor cellular energy metabolism by combining lonidamine and devimistat to disrupt multiple metabolic pathways, including glycolysis, the TCA cycle, and oxidative phosphorylation.\"},{\"question\":\"How is the synergistic antitumor effect evaluated?\",\"answer\":\"The work tests synergy in vitro and in vivo using measures such as cytotoxicity, optimal combination doses, colony formation, mitochondrial function, ATP and ROS production, apoptosis, and pharmacodynamics in an axenograft mouse model.\"},{\"question\":\"What biological effects does the combination produce in tumor cells?\",\"answer\":\"The combination increases ROS, reduces ATP generation, impairs mitochondrial morphology and function, and ultimately activates apoptosis through metabolic regulation.\"}]","Combination of lonidamine with devimistat induces synergistic antitumor effects in lung cancer via multifaceted disruption of cellular energy metabolism | PDF",1790155454,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b05c48d307121bd0d2f9d96c79d0757a.webp",983,1357,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/6ec8024dfefefc131738a6b95d62974b.webp",982,1356,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c896777fc53e721031a325450ecfad13.webp",981,1354,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/13c6340bc5558d5adc385f0ccb90fdbc.webp",980,1353]